Patents by Inventor Xinchang LIU
Xinchang LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240025905Abstract: Salts of dihydropyrimidine derivatives, complexes and uses thereof in medicine, and complexes and pharmaceutical compositions thereof. The uses of the addition salts, the complexes or the pharmaceutical compositions in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis B virus (HBV) infection.Type: ApplicationFiled: November 30, 2021Publication date: January 25, 2024Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Qingyun REN, Xinchang LIU, Yingjun ZHANG, Guanghua YAN
-
Publication number: 20230246521Abstract: A cooling cage assembly for a rotary electric motor includes a cooling stator arrangement, and a first cylindrical part and a second cylindrical part fixedly mounted against respective opposite sides of the cooling stator arrangement. The cooling stator arrangement includes a stator and cooling tiles mounted against and around the outer circumference of the stator. Each cooling tile includes at least one channel extending from an upper side to a lower side of the cooling tile. The cooling cage assembly further includes a first plurality of fluidic bridges arranged on the upper side of the cooling tiles and a second plurality of fluidic bridges arranged on the lower side of the cooling tiles to form, together with the channel(s) of the cooling tiles, a serpentine flow path, for a cooling fluid, around the outer circumference of the stator.Type: ApplicationFiled: January 17, 2023Publication date: August 3, 2023Inventors: Iván GARCIA-HERREROS, Dmitry CHECHENEV, Loïc MORENO, Johann POURCHET, Manish MITTAL, Daniele VERONESI, Xinchang LIU
-
Publication number: 20220194951Abstract: A dihydropyrimidine compound and application thereof as a drug, in particular, application as a drug for treating and preventing hepatitis B. Specifically, a compound represented by general formula (I) or (Ia) or a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein variables are as defined in the description. Use of the compound represented by general formula (I) or (Ia) or the stereoisomer, the tautomer, the oxynitride, the solvate, the metabolite, or the pharmaceutically acceptable salt thereof as a drug, in particular use as a drug for treating and preventing hepatitis B.Type: ApplicationFiled: April 29, 2020Publication date: June 23, 2022Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Qingyun REN, Yingjun ZHANG, Xinchang LIU, Siegfried GOLDMANN, Guanghua YAN, Meng WANG, Douxing LEI, Feng LI
-
Patent number: 11261190Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.Type: GrantFiled: October 17, 2018Date of Patent: March 1, 2022Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinchang Liu, Qingyun Ren, Guanghua Yan, Siegfried Goldmann, Yingjun Zhang
-
Patent number: 11142527Abstract: A dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also, use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.Type: GrantFiled: June 25, 2018Date of Patent: October 12, 2021Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Qingyun Ren, Xinchang Liu, Jianzhou Huang, Yingjun Zhang, Siegfried Goldmann
-
Publication number: 20210236493Abstract: A fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variable is as defined in the specification. The present invention also relates to the use of a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.Type: ApplicationFiled: August 27, 2019Publication date: August 5, 2021Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Jianzhou HUANG, Qingyun REN, Jinfeng XIONG, Yang LIU, Xinchang LIU, Siegfried GOLDMANN, Yingjun ZHANG, Yifeng WANG, Weishun LIU, Fangcai YU
-
Patent number: 10966970Abstract: A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.Type: GrantFiled: June 2, 2018Date of Patent: April 6, 2021Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinchang Liu, Qingyun Ren, Jianzhou Huang, Zhimin Xiong, Jinfeng Xiong, You Li, Yang Liu, Zhifu Zou, Guanghua Yan, Siegfried Goldmann, Yingjun Zhang
-
Publication number: 20200283445Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.Type: ApplicationFiled: October 17, 2018Publication date: September 10, 2020Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinchang LIU, Qingyun REN, Guanghua YAN, Siegfried GOLDMANN, Yingjun ZHANG
-
Publication number: 20200115381Abstract: A dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also, use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.Type: ApplicationFiled: June 25, 2018Publication date: April 16, 2020Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Qingyun REN, Xinchang LIU, Jianzhou HUANG, Yingjun ZHANG, Siegfried GOLDMANN
-
Publication number: 20200113879Abstract: A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.Type: ApplicationFiled: June 2, 2018Publication date: April 16, 2020Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Xinchang LIU, Qingyun REN, Jianzhou HUANG, Zhimin XIONG, Jinfeng XIONG, You LI, Yang LIU, Zhifu ZOU, Guanghua YAN, Siegfried GOLDMANN, Yingjun ZHANG
-
Patent number: 10098889Abstract: This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.Type: GrantFiled: February 1, 2016Date of Patent: October 16, 2018Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Qingyun Ren, Liang Chen, Xinchang Liu, Jinsheng Liang, Chenliang Wu, Zhifu Zou, Guanghua Yan, Desheng Huangfu, Siegfried Goldmann, Yingjun Zhang
-
Publication number: 20180263991Abstract: This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl) methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.Type: ApplicationFiled: February 1, 2016Publication date: September 20, 2018Applicant: SUNSHINE LAKE PHARMA CO., LTDInventors: Qingyun Ren, Liang CHEN, Xinchang LIU, Jinsheng LIANG, Chenliang WU, Zhifu ZOU, Guanghua YAN, Desheng HUANGFU, Siegfried GOLDMANN, Yingjun ZHANG
-
Patent number: 9771358Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.Type: GrantFiled: March 27, 2015Date of Patent: September 26, 2017Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Qingyun Ren, Xinchang Liu, Siegfried Goldmann
-
Patent number: 9643962Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (Ia), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.Type: GrantFiled: November 27, 2014Date of Patent: May 9, 2017Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Qingyun Ren, Xinchang Liu, Zhifu Zou, Linjin Tu, Yuefeng Shan, Douxing Lei, Siegfried Goldmann, Yingjun Zhang
-
Patent number: 9617252Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (1a), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.Type: GrantFiled: November 27, 2014Date of Patent: April 11, 2017Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinchang Liu, Qingyun Ren, Zhifu Zou, Jinsheng Liang, Linjin Tu, Siegfried Goldmann, Yingjun Zhang
-
Patent number: 9573941Abstract: The present invention relates to processes for preparing a dihydropyrimidine derivative having Formula (I) or a tautomer thereof having Formula (Ia), as well as a intermediate thereof. The processes of the invention have simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.Type: GrantFiled: November 27, 2014Date of Patent: February 21, 2017Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Qingyun Ren, Xinchang Liu, Zhifu Zou, Guanghua Yan, Mingchao Bi, Siegfried Goldmann, Yingjun Zhang
-
Publication number: 20160347746Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.Type: ApplicationFiled: March 27, 2015Publication date: December 1, 2016Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Qingyun Ren, Xinchang Liu, Siegfried Goldmann
-
Patent number: 9498479Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.Type: GrantFiled: November 18, 2014Date of Patent: November 22, 2016Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Xinchang Liu, Zhifu Zou, Jinsheng Liang, Siegfried Goldmann, Qingyun Ren
-
Publication number: 20160264563Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (Ia), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.Type: ApplicationFiled: November 27, 2014Publication date: September 15, 2016Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Qingyun REN, Xinchang LIU, Zhifu ZOU, Linjin TU, Yuefeng SHAN, Douxing LEI, Slegfried GOLDMANN, Yingjun ZHANG
-
Publication number: 20160264562Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (la), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.Type: ApplicationFiled: November 27, 2014Publication date: September 15, 2016Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinchang LIU, Qingyun REN, Zhifu ZOU, Jinsheng LIANG, Linjin TU, Siegfried GOLDMANN, Yingjun ZHANG